Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Gains from Investment Securities (2020 - 2022)

Historic Gains from Investment Securities for PROCEPT BioRobotics (PRCT) over the last 3 years, with Q4 2022 value amounting to $186000.0.

  • PROCEPT BioRobotics' Gains from Investment Securities rose 39062.5% to $186000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was $122000.0, marking a year-over-year increase of 1509.43%. This contributed to the annual value of $22.9 million for FY2022, which is 3580937.5% up from last year.
  • Latest data reveals that PROCEPT BioRobotics reported Gains from Investment Securities of $186000.0 as of Q4 2022, which was up 39062.5% from -$64000.0 recorded in Q4 2021.
  • Over the past 5 years, PROCEPT BioRobotics' Gains from Investment Securities peaked at $186000.0 during Q4 2022, and registered a low of -$142000.0 during Q3 2020.
  • In the last 3 years, PROCEPT BioRobotics' Gains from Investment Securities had a median value of -$20000.0 in 2021 and averaged -$2000.0.
  • Per our database at Business Quant, PROCEPT BioRobotics' Gains from Investment Securities tumbled by 23333.33% in 2021 and then soared by 39062.5% in 2022.
  • PROCEPT BioRobotics' Gains from Investment Securities (Quarter) stood at $48000.0 in 2020, then plummeted by 233.33% to -$64000.0 in 2021, then soared by 390.62% to $186000.0 in 2022.
  • Its last three reported values are $186000.0 in Q4 2022, -$64000.0 for Q4 2021, and -$16000.0 during Q3 2021.